These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1093 related articles for article (PubMed ID: 34485950)

  • 21. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.
    Tauzin A; Nayrac M; Benlarbi M; Gong SY; Gasser R; Beaudoin-Bussières G; Brassard N; Laumaea A; Vézina D; Prévost J; Anand SP; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Niessl J; Tastet O; Gokool L; Morrisseau C; Arlotto P; Stamatatos L; McGuire AT; Larochelle C; Uchil P; Lu M; Mothes W; De Serres G; Moreira S; Roger M; Richard J; Martel-Laferrière V; Duerr R; Tremblay C; Kaufmann DE; Finzi A
    Cell Host Microbe; 2021 Jul; 29(7):1137-1150.e6. PubMed ID: 34133950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
    Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
    Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
    Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern.
    Kaplonek P; Fischinger S; Cizmeci D; Bartsch YC; Kang J; Burke JS; Shin SA; Dayal D; Martin P; Mann C; Amanat F; Julg B; Nilles EJ; Musk ER; Menon AS; Krammer F; Saphire EO; Andrea Carfi ; Alter G
    Immunity; 2022 Feb; 55(2):355-365.e4. PubMed ID: 35090580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
    Keech C; Albert G; Cho I; Robertson A; Reed P; Neal S; Plested JS; Zhu M; Cloney-Clark S; Zhou H; Smith G; Patel N; Frieman MB; Haupt RE; Logue J; McGrath M; Weston S; Piedra PA; Desai C; Callahan K; Lewis M; Price-Abbott P; Formica N; Shinde V; Fries L; Lickliter JD; Griffin P; Wilkinson B; Glenn GM
    N Engl J Med; 2020 Dec; 383(24):2320-2332. PubMed ID: 32877576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.
    Kim E; Weisel FJ; Balmert SC; Khan MS; Huang S; Erdos G; Kenniston TW; Carey CD; Joachim SM; Conter LJ; Weisel NM; Okba NMA; Haagmans BL; Percivalle E; Cassaniti I; Baldanti F; Korkmaz E; Shlomchik MJ; Falo LD; Gambotto A
    Eur J Immunol; 2021 Jul; 51(7):1774-1784. PubMed ID: 33772778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
    Corbett KS; Werner AP; Connell SO; Gagne M; Lai L; Moliva JI; Flynn B; Choi A; Koch M; Foulds KE; Andrew SF; Flebbe DR; Lamb E; Nurmukhambetova ST; Provost SJ; Bock KW; Minai M; Nagata BM; Ry AV; Flinchbaugh Z; Johnston TS; Mokhtari EB; Mudvari P; Henry AR; Laboune F; Chang B; Porto M; Wear J; Alvarado GS; Boyoglu-Barnum S; Todd JM; Bart B; Cook A; Dodson A; Pessaint L; Steingrebe K; Elbashir S; Sriparna M; Pekosz A; Andersen H; Wu K; Edwards DK; Kar S; Lewis MG; Boritz E; Moore IN; Carfi A; Suthar MS; McDermott A; Roederer M; Nason MC; Sullivan NJ; Douek DC; Graham BS; Seder RA
    Nat Immunol; 2021 Oct; 22(10):1306-1315. PubMed ID: 34417590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
    Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
    Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.
    Klingler J; Lambert GS; Itri V; Liu S; Bandres JC; Enyindah-Asonye G; Liu X; Simon V; Gleason CR; Kleiner G; Chiu HP; Hung CT; Kowdle S; Amanat F; Lee B; Zolla-Pazner S; Upadhyay C; Hioe CE
    Front Immunol; 2021; 12():759688. PubMed ID: 34987505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
    Solforosi L; Kuipers H; Jongeneelen M; Rosendahl Huber SK; van der Lubbe JEM; Dekking L; Czapska-Casey DN; Izquierdo Gil A; Baert MRM; Drijver J; Vaneman J; van Huizen E; Choi Y; Vreugdenhil J; Kroos S; de Wilde AH; Kourkouta E; Custers J; van der Vlugt R; Veldman D; Huizingh J; Kaszas K; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; Barouch DH; Böszörményi KP; Stammes MA; Kondova I; Verschoor EJ; Verstrepen BE; Koopman G; Mooij P; Bogers WMJM; van Heerden M; Muchene L; Tolboom JTBM; Roozendaal R; Brandenburg B; Schuitemaker H; Wegmann F; Zahn RC
    J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33909009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity.
    Richardson SI; Manamela NP; Motsoeneng BM; Kaldine H; Ayres F; Makhado Z; Mennen M; Skelem S; Williams N; Sullivan NJ; Misasi J; Gray GG; Bekker LG; Ueckermann V; Rossouw TM; Boswell MT; Ntusi NAB; Burgers WA; Moore PL
    Cell Rep Med; 2022 Feb; 3(2):100510. PubMed ID: 35233544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.
    van Doremalen N; Fischer RJ; Schulz JE; Holbrook MG; Smith BJ; Lovaglio J; Petsch B; Munster VJ
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.